Murat Kurt

1.1k total citations
67 papers, 754 citations indexed

About

Murat Kurt is a scholar working on Economics and Econometrics, Oncology and Surgery. According to data from OpenAlex, Murat Kurt has authored 67 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 17 papers in Oncology and 15 papers in Surgery. Recurrent topics in Murat Kurt's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Dental materials and restorations (11 papers). Murat Kurt is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Dental materials and restorations (11 papers). Murat Kurt collaborates with scholars based in United States, United Kingdom and Türkiye. Murat Kurt's co-authors include Çağrı Ural, Tolga Külünk, Şafak Külünk, Steven A. Smith, Bora Özden, A.G. de Kok, Nilay D. Shah, Duygu Saraç, Y. Şinasi Saraç and Sandra C. Bryant and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Murat Kurt

55 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Murat Kurt United States	17	313	300	92	85	73	67	754
Paolo De Angelis Italy	14	322 1.0×	243 0.8×	17 0.2×	32 0.4×	112 1.5×	71	793
Sorin Teich United States	16	306 1.0×	268 0.9×	14 0.2×	116 1.4×	60 0.8×	71	860
Giovanni Bruno Italy	13	132 0.4×	155 0.5×	11 0.1×	65 0.8×	83 1.1×	76	682
Lauren Bohner Germany	19	546 1.7×	400 1.3×	5 0.1×	163 1.9×	107 1.5×	75	1.0k
Adilson Luiz Ramos Brazil	15	270 0.9×	525 1.8×	4 0.0×	46 0.5×	52 0.7×	74	890
Soheila Aghlmandi Switzerland	16	33 0.1×	29 0.1×	66 0.7×	11 0.1×	546 7.5×	39	972
Prabhadevi C. Maganur Saudi Arabia	12	538 1.7×	108 0.4×	6 0.1×	210 2.5×	35 0.5×	49	901
Christoph M. Ziegler Germany	14	564 1.8×	70 0.2×	6 0.1×	16 0.2×	204 2.8×	31	1.3k
Dong Hwan Lee South Korea	19	65 0.2×	81 0.3×	6 0.1×	40 0.5×	213 2.9×	76	1.0k
Zeki Akkuş Türkiye	17	257 0.8×	95 0.3×	4 0.0×	19 0.2×	113 1.5×	55	815

Countries citing papers authored by Murat Kurt

Since Specialization

Citations

This map shows the geographic impact of Murat Kurt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murat Kurt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murat Kurt more than expected).

Fields of papers citing papers by Murat Kurt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murat Kurt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murat Kurt. The network helps show where Murat Kurt may publish in the future.

Co-authorship network of co-authors of Murat Kurt

This figure shows the co-authorship network connecting the top 25 collaborators of Murat Kurt. A scholar is included among the top collaborators of Murat Kurt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murat Kurt. Murat Kurt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geynisman, Daniel M., Kateryna Chepynoga, Ashley Tate, et al.. (2025). Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial. Clinical Genitourinary Cancer. 23(3). 102335–102335.

Roodhart, Jeanine M.L., et al.. (2025). Can overall survival (OS) benefit be predicted from improvements in progression-free survival (PFS) for previously untreated metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology. 43(4_suppl). 222–222.

Brodtkorb, Thor‐Henrik, et al.. (2024). Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of Medical Economics. 27(1). 473–481. 1 indexed citations

Brodtkorb, Thor‐Henrik, C Knight, Murat Kurt, et al.. (2024). Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of Medical Economics. 27(1). 543–553. 3 indexed citations

Chepynoga, Kateryna, et al.. (2023). P27 The Impact of Incorporating Survival Heterogeneity into Modeling of Survival Outcomes for Patients with Muscle-Invasive Bladder Cancer after Radical Resection: Analyses from a Retrospective Real-World Study in France. Value in Health. 26(6). S6–S6. 1 indexed citations

Awan, Farrukh T., et al.. (2023). The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US). Blood. 142(Supplement 1). 2330–2330.

Kanters, Steve, Howard S. Frıedman, Prakash Navaratnam, et al.. (2023). CO205 Evaluating Disease-Free Survival (DFS) As a Surrogate Endpoint (SE) for Overall Survival (OS) in Muscle-Invasive Urothelial Carcinoma (MIUC): An Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare Data. Value in Health. 26(6). S54–S54.

Broughton, Edward, et al.. (2022). POSB8 Efficacy and Safety Results from Randomized Controlled Trials (RCTS) Evaluating Adjuvant Treatment after Radical Resection (RR) of Muscle Invasive Urothelial Carcinoma (MIUC): A Systematic Literature Review (SLR). Value in Health. 25(1). S26–S26.

Escudier, B., Robert J. Motzer, Matthew D. Dyer, et al.. (2022). 1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC). Annals of Oncology. 33. S1212–S1212.

10.

Kurt, Murat, et al.. (2022). POSB302 Assessing the Viability of a Surrogacy Relationship between Disease-Free Survival (DFS) and Overall Survival (OS) for the Patients in Clinical Trials for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) Following Radical Cystectomy.. Value in Health. 25(1). S203–S203. 1 indexed citations

11.

Sofeu, Casimir Ledoux, Anne-Françoise Gaudin, Murat Kurt, et al.. (2021). Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open. 7(1). 100340–100340. 12 indexed citations

12.

Klijn, S., et al.. (2021). What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma. PharmacoEconomics. 39(3). 345–356. 16 indexed citations

13.

Kurt, Murat, et al.. (2020). Üniversite Öğrencilerinde Somatik Belirtiler, Bağlanma Stilleri ve Suçluluk Utanç Duyguları Arasındaki İlişkinin İncelenmesi. Anemon Muş Alparslan Üniversitesi Sosyal Bilimler Dergisi. 8(2). 383–393. 1 indexed citations

14.

Malcolm, Bill, et al.. (2020). PDG5 Updated Lifetime Survival Estimates for Nivolumab+ipilimumab in Previously Untreated Advanced/Metastatic Intermediate- or Poor-Risk Renal Cell Carcinoma (1L aRCC). Value in Health. 23. S521–S521. 1 indexed citations

15.

Malcolm, Bill, et al.. (2020). PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update. Value in Health. 23. S428–S428. 1 indexed citations

16.

Karamustafaoğlu, Orhan, et al.. (2018). OTİZMLİ ÖĞRENCİLERE BİR EĞİTSEL OYUNLA “İÇ ORGANLARINI TANIYABİLME” KONUSUNUN ÖĞRETİMİ. Abant İzzet Baysal Üniversitesi Eğitim Fakültesi Dergisi. 18(4). 1887–1902. 2 indexed citations

17.

Aygün, Dursun, Ersoy Kocabıçak, Musa Onar, et al.. (2013). Syncope Associated with Subthalamic Nucleus Deep Brain Stimulation in a Patient with Parkinson’s Disease. SHILAP Revista de lepidopterología. 2013. 1–2. 1 indexed citations

18.

Kurt, Murat, et al.. (2012). Effects of different surface treatments on the bond strength of glass fiber-reinforced composite root canal posts to composite core material. Journal of Dental Sciences. 7(1). 20–25. 17 indexed citations

19.

Kurt, Murat, et al.. (2011). Effect of pre‐processing methods on bond strength between acrylic resin teeth and acrylic denture base resin. Gerodontology. 29(2). e357–62. 18 indexed citations

20.

Ural, Çağrı, Tolga Külünk, Şafak Külünk, & Murat Kurt. (2010). The Effect of Laser Treatment on Bonding Between Zirconia Ceramic Surface and Resin Cement. Acta Odontologica Scandinavica. 68(6). 354–359. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact